16th Annual Scientific Meeting
19 – 21 February, 2020 // Grand Hyatt, Washington DC
Distinguished Poster Award Recipient:
|
|||
| Up-Front Matching for Prospective Observational Studies to Mimic Randomization (Turkoz) | |||
|
All Poster PDFs and Abstracts are available at the end of the second day. |
|||
19 February 2020 |
|||
| Welcome from the President | Carla Canuso slides video |
||
| Unresolved Problems in Neuroscience Drug Development | |||
| Drugs with abuse liability: Issues facing their use as treatments for psychiatric disorders and how to address them
|
Chair: Walter Dunn slides video Discussants: Jerry Sanacora slides videoCharles Nemeroff slides videoRaye Litten slides video |
||
| Panel/Audience Discussion | video |
||
| Are current digital measures ready for prime time? | Chair: Phil Harvey Discussants: Elektra Papadopoulos slides videoGreg Strauss slides videoValentina Mantua* |
||
| Panel/Audience Discussion | video |
||
|
Wednesday Working Group Sessions |
|||
| Artificial Intelligence (AI) and Machine Learning (ML) for CNS Clinical Trials | Chairs: Adam Butler Larry Alphs summary |
||
| Autism Spectrum Disorder | Chairs: Valentina Mantua Tiffany Farchione Celso Arango summary |
||
| Behavioral and Psychiatric Symptoms in Dementia—Agitation Subgroup | Chairs: Cedric O’Gorman Paul Rosenberg summary |
||
| Developing Integrated Interventions: Clinical Trials for Drug/Neuromodulation-Psychotherapy Combinations | Chairs: Walter Dunn Zimri Yaseen summary |
||
| Estimands and Missing Data | Chairs: Pilar Lim Elena Polverejan summary |
||
| Prevention Trials in Alzheimer’s Disease | Chairs: Holly Posner Phil Harvey |
||
20 February 2020 |
|||
| Andrew C. Leon Distinguished Career Award Presentation | Steve Marder Carla Canuso slidesRobert Heinssen video |
||
| Enhancing drug development through artificial intelligence (AI) and machine learning (ML) | Chairs: Adam Butler Larry Alphs Saeed Ahmed |
||
| Introduction: Improving clinical trials with modern techniques | Adam Butler slides video |
||
| What is artificial intelligence? | Saeed Ahmed slides video |
||
| Applications of machine learning for psychiatry | Joe Geraci slides video |
||
| Using AI/ML to differentiate drug and placebo responders in mood disorders: Offering the opportunity for enhanced patient selection | Jane Tiller slides video |
||
| AI-enabled digital phenotyping as a vehicle for clinical trial qualification and tracking of change during intervention | Dennis Wall* |
||
| Regulatory considerations when utilizing AI and ML applications in the design and execution of a CNS clinical trial | David Millis slides video |
||
| Panel Discussion | Discussant: Vikas Mohan Sharma slides video |
||
| Summary | |||
| The Brain – Gut Axis in Psychiatry and Neurology: Focus on the Microbiome | Chairs: Jill Rasmussen Ron Marcus |
||
| Introduction | Jill Rasmussen slides video |
||
| Microbes, brain and behavior- Focus on depression | Ted Dinan slides video |
||
| The brain immune gut axis- a big approach to developing new medications for psychiatric disorders in the new decade | Robert Yolken slides video |
||
| Microbiome and Alzheimer’s disease | Miia Kivipelto slides video |
||
| Microbiome and Parkinson disease: Therapeutic implications | Peter LeWitt slides video |
||
| Regulatory considerations for microbiome based therapeutics | Paul Carlson slides video Luca Pani video |
||
| Panel / Audience Discussion | Facilitator: Ron Marcus video |
||
| Is There a Fundamental Rethinking in the Way We Plan Clinical Trials? The Estimand Change in Mindset | Chairs: Pilar Lim Michael Davis Steve Brannan |
||
| Introduction | Pilar Lim slides video |
||
| Introduction to the ICH E9(R1) Addendum on “Estimands and Sensitivity Analysis in Clinical Trials”: A clinical perspective | Florence Butlen-Ducuing slides video |
||
| Putting the ICH E9(R1) Guidance into practice – A multi-disciplinary collaboration | Elena Polverejan slides video |
||
| Development of an estimand for acute treatment of Major Depressive Disorder trials: Keeping the new mindset in mind | Zimri Yaseen slides video |
||
| Regulatory implications of the ICH E9(R1) Guidance | Robert Temple slides video |
||
| Panel and Regulatory Discussion | Facilitator: Michael Davis Panelists: James Hung Michael O’Kelly Marc Walton video |
||
| Summary | Michael Davis |
||
| Poster Session/Reception | Poster PDFs and Abstracts | ||
21 February 2020
|
|||
|
Friday Working Group Sessions |
|||
| Assessment Methods and Endpoints for Rapid-Acting Antidepressants-RAADs | Chairs: Mark Opler Elizabeth Ballard Christian Yavorsky summary |
||
| Behavioral and Psychiatric Symptoms in Dementia—Apathy Subgroup | Chairs: Krista Lanctôt David Miller summary |
||
| Curriculum Development – Advanced CNS Clinical Trials Course | Chairs: Carla Canuso Kari Nations summary |
||
| Innovative Technologies for Clinical Trials | Chairs: Richard Keefe Michael Davis summary |
||
| Orphan Diseases | Chairs: Joan Busner Gahan Pandina Ravi Anand summary |
||
| Role of Reward Processing Assessment as a Tool in Drug Development | Chairs: Larry Ereshefsky Raimund Buller |
||
| Introduction | Raimund Buller Larry Ereshefsky video |
||
| The neurobiology of anhedonia: Circuitry and relevance to drug development and patient stratification | Diego Pizzagalli slides video |
||
| Reward processing mechanisms underlying negative symptoms in schizophrenia | Gregory Strauss slides video |
||
| Reward processing in neurological disorders: Focus on Parkinson’s disease | Masud Husain slides video |
||
| Pragmatic aspects of including reward processing tasks in drug development trials | Stephane Pollentier slides video |
||
| Comment: Translational considerations – NIMH | Sarah Lisanby slides video |
||
| Regulatory view on use of reward processing in patient segmentation and as a marker for treatment response | Tiffany Farchione slides video |
||
| Panel / Audience Discussion | video |
||
| Summary | |||
| Meeting Adjourned
*Slides not released |
Ramy Mahmoud video |
||